Current Agency Expectations for Approval for Biosimilars

Biosimilars are a relatively new subset of biopharmaceuticals, with the biotechnology industry finally maturing such that off-patent generic-type products increasingly will be entering major markets. So far, more than 20 biosimilars for a limited number of reference products have been approved in major markets, primarily the European Union. Only two products have been formally approved as biosimilars in the United States. The parent field of biopharmaceuticals itself continues to exhibit a poor supporting infrastructure of information resources. Those biopharmaceutical and biosimilar information resources that do exist generally are limited in number, diversity, and sophistication.

    Related Conference of Current Agency Expectations for Approval for Biosimilars

    February 24-25, 2025

    2nd International Conference on Pharmacognosy

    Madrid, Spain
    February 27-28, 2025

    8th International on Pharmacy and Pharmaceutical Conference

    Prague, Czech Republic
    March 10-11, 2025

    35th Annual European Pharma Congress

    Rome, Italy
    April 14-15, 2025

    18th European Biosimilars Congress

    Paris, France
    April 24-25, 2025

    18th World Drug Delivery Summit

    London, UK
    May 05-06, 2025

    19th World Drug Delivery Summit

    Vancouver, Canada
    June 16-17, 2025

    3rd Global Online Summit on Nanoscience and Nanotechnology

    Zurich, Switzerland
    June 23-24, 2025

    38th World Congress on Pharmacology

    Aix-en-Provence, France
    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland

    Current Agency Expectations for Approval for Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in